Antiplatelet Therapy for Patients Undergoing Transcatheter Aortic Valve Implantation

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1016 participants.

Also called NCT02247128

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose prevention
Phase
Phase 4
Enrolled
  • 1,016 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02247128
Other papers using this trial's data
  • Anticoagulation with or without Clopidogrel after Transcatheter Aortic-Valve Implantation The New England journal of medicine, 2020-04-30 DOI, PubMed 32223116
  • Aspirin with or without Clopidogrel after Transcatheter Aortic-Valve Implantation The New England journal of medicine, 2020-10-08 DOI, PubMed 32865376

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Belgium, Czechia, Luxembourg, Netherlands (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02247128. Randomized; no masking; primary purpose prevention. Start 2014-01 (registry gives no type); primary completion 2020-03 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Antiplatelet Therapy for Patients Undergoing Transcatheter Aortic Valve Implantation
Acronym
POPular-TAVI
Condition
Aortic Valve Disease
Condition
Stroke
Condition
Bleeding
Intervention (Drug)
Aspirin + clopidogrel
Intervention (Drug)
Aspirin monotherapy
Intervention (Drug)
OAC + clopicogrel
Intervention (Drug)
OAC monotherapy
Lead sponsor
St. Antonius Hospital (class: other)

Record details

Record id
cardio:ct-nct02247128
Content hash
dcb9577cda8fd6a8aa85ea37611302940cdc39bbbed41fdc403cf0e04cdd4276